The global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market size was valued at US$ 15.34 billion in 2024 and is projected to reach US$ 20.67 billion by 2030, at a CAGR of 5.1% during the forecast period 2024-2030.
United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist market size was valued at US$ 5.01 billion in 2024 and is projected to reach US$ 6.49 billion by 2030, at a CAGR of 4.4% during the forecast period 2024-2030.
Drugs that block the action of angiotensin II for treating hypertension and other cardiovascular conditions.
Steady growth supported by increasing prevalence of hypertension and heart failure. Expanding indications in kidney disease and diabetic nephropathy. Development of fixed-dose combinations for improved efficacy and adherence.
Report Overview
This report provides a deep insight into the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-Peptide Drugs of Angiotensin II Receptor Antagonist market in any manner.
Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Pfizer
- Novartis
- Merck
- AstraZeneca
- Jhonson and Johnson
- Eli Lilly
- Sanofi
- Bristol-Myers Squibb
- Bayer
- GSK
- Teva Pharmaceutical
- Shenzhen Salubris Pharmaceuticals
- Sun Pharmaceutical
- Mylan
- Alembic Pharmaceuticals
- Lupin
- Aurobindo Pharma
- Amneal Pharmaceuticals
- Boehringer Ingelheim
Market Segmentation (by Type)
- Valsartan
- Irbesartan
- Candesartan Cilexetil
- Eprosartan
- Irbesartan
- Telmisartan
- losartan
- Olmesartan Medoxomil
- Allisartan isoproxil
Market Segmentation (by Application)
- High Blood Pressure
- Congestive Heart Failure
- Left Ventricular Hypertrophy
- Atherosclerosis
- Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
- Overview of the regional outlook of the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the
major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Non-Peptide Drugs of Angiotensin II Receptor Antagonist
1.2 Key Market Segments
1.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Segment by Type
1.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Overview
2.1 Global Market Overview
2.1.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Competitive Landscape
3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Manufacturers (2019-2024)
3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Sites, Area Served, Product Type
3.6 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Competitive Situation and Trends
3.6.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Chain Analysis
4.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Type (2019-2024)
6.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Type (2019-2024)
6.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Price by Type (2019-2024)
7 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Sales by Application (2019-2024)
7.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (M USD) by Application (2019-2024)
7.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Growth Rate by Application (2019-2024)
8 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Segmentation by Region
8.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Region
8.1.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Region
8.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Region
8.2 North America
8.2.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Pfizer
9.1.1 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.1.2 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.1.4 Pfizer Business Overview
9.1.5 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist SWOT Analysis
9.1.6 Pfizer Recent Developments
9.2 Novartis
9.2.1 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.2.2 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.2.4 Novartis Business Overview
9.2.5 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist SWOT Analysis
9.2.6 Novartis Recent Developments
9.3 Merck
9.3.1 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.3.2 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.3.4 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist SWOT Analysis
9.3.5 Merck Business Overview
9.3.6 Merck Recent Developments
9.4 AstraZeneca
9.4.1 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.4.2 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.4.4 AstraZeneca Business Overview
9.4.5 AstraZeneca Recent Developments
9.5 Jhonson and Johnson
9.5.1 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.5.2 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.5.4 Jhonson and Johnson Business Overview
9.5.5 Jhonson and Johnson Recent Developments
9.6 Eli Lilly
9.6.1 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.6.2 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.6.4 Eli Lilly Business Overview
9.6.5 Eli Lilly Recent Developments
9.7 Sanofi
9.7.1 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.7.2 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.7.4 Sanofi Business Overview
9.7.5 Sanofi Recent Developments
9.8 Bristol-Myers Squibb
9.8.1 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.8.2 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.8.4 Bristol-Myers Squibb Business Overview
9.8.5 Bristol-Myers Squibb Recent Developments
9.9 Bayer
9.9.1 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.9.2 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.9.4 Bayer Business Overview
9.9.5 Bayer Recent Developments
9.10 GSK
9.10.1 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.10.2 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.10.4 GSK Business Overview
9.10.5 GSK Recent Developments
9.11 Teva Pharmaceutical
9.11.1 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.11.2 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.11.4 Teva Pharmaceutical Business Overview
9.11.5 Teva Pharmaceutical Recent Developments
9.12 Shenzhen Salubris Pharmaceuticals
9.12.1 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.12.2 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.12.4 Shenzhen Salubris Pharmaceuticals Business Overview
9.12.5 Shenzhen Salubris Pharmaceuticals Recent Developments
9.13 Sun Pharmaceutical
9.13.1 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.13.2 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.13.4 Sun Pharmaceutical Business Overview
9.13.5 Sun Pharmaceutical Recent Developments
9.14 Mylan
9.14.1 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.14.2 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.14.4 Mylan Business Overview
9.14.5 Mylan Recent Developments
9.15 Alembic Pharmaceuticals
9.15.1 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.15.2 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.15.4 Alembic Pharmaceuticals Business Overview
9.15.5 Alembic Pharmaceuticals Recent Developments
9.16 Lupin
9.16.1 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.16.2 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.16.4 Lupin Business Overview
9.16.5 Lupin Recent Developments
9.17 Aurobindo Pharma
9.17.1 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.17.2 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.17.4 Aurobindo Pharma Business Overview
9.17.5 Aurobindo Pharma Recent Developments
9.18 Amneal Pharmaceuticals
9.18.1 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.18.2 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.18.4 Amneal Pharmaceuticals Business Overview
9.18.5 Amneal Pharmaceuticals Recent Developments
9.19 Boehringer Ingelheim
9.19.1 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
9.19.2 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
9.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Market Performance
9.19.4 Boehringer Ingelheim Business Overview
9.19.5 Boehringer Ingelheim Recent Developments
10 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Region
10.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast
10.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country
10.2.3 Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Region
10.2.4 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Type (2025-2030)
11.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Type (2025-2030)
11.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Application (2025-2030)
11.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units) Forecast by Application
11.2.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Comparison by Region (M USD)
Table 5. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2022)
Table 10. Global Market Non-Peptide Drugs of Angiotensin II Receptor Antagonist Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Sites and Area Served
Table 12. Manufacturers Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Type
Table 13. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-Peptide Drugs of Angiotensin II Receptor Antagonist
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
Table 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Type (K Units)
Table 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (M USD)
Table 24. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units) by Type (2019-2024)
Table 25. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Type (2019-2024)
Table 26. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Type (2019-2024)
Table 28. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Price (USD/Unit) by Type (2019-2024)
Table 29. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units) by Application
Table 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application
Table 31. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Application (2019-2024) & (K Units)
Table 32. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application (2019-2024)
Table 33. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2019-2024)
Table 35. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Region (2019-2024) & (K Units)
Table 37. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Region (2019-2024)
Table 38. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Country (2019-2024) & (K Units)
Table 39. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Region (2019-2024) & (K Units)
Table 41. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales by Region (2019-2024) & (K Units)
Table 43. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 44. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 45. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Pfizer Business Overview
Table 47. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist SWOT Analysis
Table 48. Pfizer Recent Developments
Table 49. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 50. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 51. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Novartis Business Overview
Table 53. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist SWOT Analysis
Table 54. Novartis Recent Developments
Table 55. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 56. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 57. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist SWOT Analysis
Table 59. Merck Business Overview
Table 60. Merck Recent Developments
Table 61. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 62. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 63. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca Recent Developments
Table 66. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 67. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 68. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Jhonson and Johnson Business Overview
Table 70. Jhonson and Johnson Recent Developments
Table 71. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 72. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 73. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Eli Lilly Business Overview
Table 75. Eli Lilly Recent Developments
Table 76. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 77. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 78. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Sanofi Business Overview
Table 80. Sanofi Recent Developments
Table 81. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 82. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 83. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Recent Developments
Table 86. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 87. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 88. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Bayer Business Overview
Table 90. Bayer Recent Developments
Table 91. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 92. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 93. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. GSK Business Overview
Table 95. GSK Recent Developments
Table 96. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 97. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 98. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Teva Pharmaceutical Business Overview
Table 100. Teva Pharmaceutical Recent Developments
Table 101. Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 102. Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 103. Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Shenzhen Salubris Pharmaceuticals Business Overview
Table 105. Shenzhen Salubris Pharmaceuticals Recent Developments
Table 106. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 107. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 108. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Sun Pharmaceutical Business Overview
Table 110. Sun Pharmaceutical Recent Developments
Table 111. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 112. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 113. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Mylan Business Overview
Table 115. Mylan Recent Developments
Table 116. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 117. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 118. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Alembic Pharmaceuticals Business Overview
Table 120. Alembic Pharmaceuticals Recent Developments
Table 121. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 122. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 123. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Lupin Business Overview
Table 125. Lupin Recent Developments
Table 126. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 127. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 128. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Aurobindo Pharma Business Overview
Table 130. Aurobindo Pharma Recent Developments
Table 131. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 132. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 133. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Amneal Pharmaceuticals Business Overview
Table 135. Amneal Pharmaceuticals Recent Developments
Table 136. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Basic Information
Table 137. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Overview
Table 138. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Boehringer Ingelheim Business Overview
Table 140. Boehringer Ingelheim Recent Developments
Table 141. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Region (2025-2030) & (K Units)
Table 142. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Region (2025-2030) & (M USD)
Table 143. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Country (2025-2030) & (K Units)
Table 144. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 145. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Country (2025-2030) & (K Units)
Table 146. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 147. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Region (2025-2030) & (K Units)
Table 148. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Region (2025-2030) & (M USD)
Table 149. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Country (2025-2030) & (K Units)
Table 150. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 151. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Consumption Forecast by Country (2025-2030) & (Units)
Table 152. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 153. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Type (2025-2030) & (K Units)
Table 154. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type (2025-2030) & (M USD)
Table 155. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Price Forecast by Type (2025-2030) & (USD/Unit)
Table 156. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units) Forecast by Application (2025-2030)
Table 157. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Non-Peptide Drugs of Angiotensin II Receptor Antagonist
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (M USD), 2019-2030
Figure 5. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (M USD) (2019-2030)
Figure 6. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (M USD)
Figure 11. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Share by Manufacturers in 2023
Figure 12. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Manufacturers in 2023
Figure 13. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-Peptide Drugs of Angiotensin II Receptor Antagonist Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type
Figure 18. Sales Market Share of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Type (2019-2024)
Figure 19. Sales Market Share of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Type in 2023
Figure 20. Market Size Share of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Type (2019-2024)
Figure 21. Market Size Market Share of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application
Figure 24. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application (2019-2024)
Figure 25. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application in 2023
Figure 26. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2019-2024)
Figure 27. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application in 2023
Figure 28. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Region (2019-2024)
Figure 30. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Country in 2023
Figure 32. U.S. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Country in 2023
Figure 37. Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Region in 2023
Figure 44. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (K Units)
Figure 50. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Country in 2023
Figure 51. Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Forecast by Application (2025-2030)
Figure 66. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share Forecast by Application (2025-2030)
